References
  1. Julian Gardiner, Jude Oben, Alastair Sutcliffe. Obesity as a driver of international differences in COVID-19 death rates. Diabetes Obes Metab. 2021 Jul;23(7):1463-1470.
  2. Zhang X, Zhang W, Chen S. Shanghai’s life-saving efforts against the current omicron wave of the COVID-19 pandemic. Lancet 2022; 399: 2011–12.
  3. Fangfang Sun, Yanwei Lin, Xiaodong Wang, Yuan Gao, Shuang Ye.Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection. Lancet Infect Dis. 2022 Sep;22(9):1279.
  4. Elisabeth Mahase. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ,2021 Nov 8;375: n2713.
  5. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs. placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324(22):2292–2300.
  6. Zhang Y, Li H, Zhang J, et al. The clinical characteristics and outcomes of diabetes mellitus and secondary hyperglycaemia patients with coronavirus disease 2019: A single-centre, retrospective, observational study in Wuhan. Diabetes Obes Metab. 2020.
  7. Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020; 22(10): 1897- 1906.
  8. National Health Commission of the People’s Republic of China. Diagnosis and treatment plan for COVID-19 (trial version 9). Int J Epidemiol Infect Dis 2022; 49: 73–80.
  9. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med 2022; 386:1397-408.
  10. A living WHO guideline on drugs for covid-19. BMJ 2022; 377: o1045.
  11. Y. Mo, K. K.W. To, R. Zhou, et al. Mitochondrial dysfunction associates with acute T lymphocytopenia and impaired functionality in COVID-19 patients. Front. Immunol. 2021(12), 799896.
  12. L. Gibellini, S. DeBiasi, A. Paolini, et al. Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia. EMBO Mol. Med. 2020(12), e13001.
  13. X. Gao, B. Zhu, Y. Wu, et al. TFAM-dependent mitochondrial metabolism is required for alveolar macrophage maintenance and homeostasis. J. Immunol. 2022(208), 1456–1466.
  14. Bibo Zhu, Xiaoqin Wei, Harish Narasimhan et al. Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19. Sci Immunol. 2023(23); eadf 0348.